Close Menu

NEW YORK (GenomeWeb) – Danaher said today that it plans to acquire Cepheid for nearly $4 billion in cash. The deal is expected to close by the end of the year.

Under the terms of the merger agreement, Danaher will acquire all of Cepheid's outstanding stock for $53.00 per share, a 54 percent premium to Friday's close. Including Cepheid's indebtedness, this represents a total enterprise value of approximately $4 billion. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.